Advanced Cancer Detection with Precision Methods

Introduction

Unlock the future of breast cancer diagnostics with a method that precisely identifies the critical transition from epithelial to mesenchymal states in cancer cells. This unique approach offers an advanced, highly accurate method for detecting the aggressive progression in breast cancer, crucial for early intervention and tailored treatments.

Using a blend of innovative compositions and techniques, this method sheds light on cancer’s molecular shifts. Early identification of these cellular changes empowers healthcare providers to adapt treatment strategies promptly, potentially slowing cancer’s spread and improving patient outcomes. This technology stands out for its precision and reliability in tracking the complex biology of cancer cells, enabling a nuanced understanding that conventional diagnostic tools may miss.

For biotech firms, oncology-focused research labs, and clinical diagnostic developers, this technology opens the door to a new level of cancer detection and research. Not only does it facilitate earlier and more accurate cancer identification, but it also aligns with the industry’s movement towards personalized medicine, offering insights that could lead to more effective, patient-specific treatments.

By licensing this patent, your organization will pioneer a powerful tool in the fight against breast cancer, gaining a competitive advantage in delivering groundbreaking diagnostic solutions. This is more than just a technology—it’s a step toward a future where breast cancer can be detected and managed more effectively, providing hope and empowerment for patients and their families.

Please see terms and conditions

Abstract
Claims

There is disclosed a method for selectively detecting epithelial to mesenchymal transition (EMT) phenotypic cells but not noncancerous/normal epithelial cells and breast fibroblasts in a biological sample or a patient. The compositions comprise novel binding peptides that specifically bind to EMT cancer cells. EMT phenotypic cells can be identified using the specific peptides and quantitatively measured by detection of a complex of the peptide and a detectable marker. Further, nanodevices incorporating specific EMT phage ligand may be used to identify EMT cancer cells in vivo. Also disclosed are the novel binding phage peptides, and compositions and nanodevices containing the phage ligand for carrying out methods of the invention.

What is claimed is:

1. An isolated peptide consisting of amino acid sequence of LGLRGSL (SEQ ID NO: 1), or GTFLFS (SEQ ID NO: 3) or PNLPWVP (SEQ ID NO: 4) complexed with a detectable label.

2. The peptide of claim 1 wherein the peptide is complexed with a radio-isotope, biotin, digoxygenin, methyl, fluorescence or a chemiluminescent.

3. An expression vector comprising a nucleic acid sequence encoding the amino acid sequence consisting of LGLRGSL (SEQ ID NO:1), or GTLFLFS (SEQ ID NO: 3) or PNLPWVP (SEQ ID NO: 4) operably linked to a promoter.

4. A method of determining whether a subject has or is at risk for metastatic breast cancer, the method comprising:

providing a peptide complex, wherein the peptide complex specifically binds to EMT phenotypic breast cancer cells and does not specifically bind to non-cancer cells,

delivering the peptide complex to a subject; and

detecting the peptide complex in a subject, wherein the presence of the peptide complex indicates that the subject has or is at risk for a metastatic breast cancer;

wherein the peptide has the sequence selected from the group consisting of SEQ ID NOs: 1-7, 9-14, 16-24 and 25.

5. A method of determining whether a subject has or is at risk for metastatic breast cancer, the method comprising:

providing a biological sample from the subject;

contacting the biological sample with the peptide of claim 2, wherein the peptide specifically binds to EMT phenotypic breast cancer cells and does not specifically bind to non-cancer cells; and

detecting the binding of the peptide to EMT phenotypic breast cancer cells in the biological sample, thereby determining the biological sample contains EMT phenotypic breast cancer cells,

wherein the presence of EMT phenotypic breast cancer cells in the biological sample indicates that the subject has or is at risk for a metastatic breast cancer.

6. The method of claim 4, wherein the biological sample is a tissue biopsy, a lymph node biopsy tumor, serum, blood, or plasma sample.

Title

Methods and compositions for the identification of epithelial to mesenchymal breast cancer

Inventor(s)

Deepa Bedi, Kelvin Jones

Assignee(s)

Tuskegee University

Patent #

11624748

Patent Date

April 11, 2023